Glen Harbor Capital Management’s Charles River Laboratories CRL Stock Holding History

Glen Harbor Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.44M	Sell	10,880 -6,834	-39%	-$916K	0.03%	391
2019 Q2	$2.51M	Buy	17,714 +3,910	+28%	+$530K	0.05%	295
2019 Q1	$2M	Buy	13,804 +4,148	+43%	+$545K	0.04%	319
2018 Q4	$1.09M	Sell	9,656 -2,312	-19%	-$289K	0.03%	414
2018 Q3	$1.61M	Buy	11,968 +1,632	+16%	+$201K	0.03%	374
2018 Q2	$1.16M	Sell	10,336 -5,372	-34%	-$581K	0.02%	402
2018 Q1	$1.68M	Sell	15,708 -102	-0.6%	-$11K	0.04%	314
2017 Q4	$1.73M	Buy	15,810 +9,078	+135%	+$988K	0.04%	327
2017 Q3	$727K	Buy	6,732 +1,020	+18%	+$105K	0.02%	481
2017 Q2	$578K	Buy	5,712 +680	+14%	+$62.6K	0.01%	554
2017 Q1	$452K	Sell	5,032 -204	-4%	-$17.3K	0.01%	579
2016 Q4	$399K	Buy	+5,236	New	+$398K	0.01%	558

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glen Harbor Capital Management's CRL Position: Q3 2019 in Review

Glen Harbor Capital Management reduced its Charles River Laboratories (CRL) stake by 39% in Q3 2019, selling an estimated $916K and leaving 10,880 shares worth $1.44M. The position accounts for 0.03% of the portfolio, ranked #391.

Glen Harbor Capital Management first reported a position in CRL in Q4 2016 and has held it in 12 quarters since. The position peaked at $2.51M in Q2 2019. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

Glen Harbor Capital Management held 10,880 shares of Charles River Laboratories worth $1.44M as of Q3 2019.
Glen Harbor Capital Management sold 6,834 Charles River Laboratories shares in Q3 2019, an estimated $916K.
Charles River Laboratories made up 0.03% of Glen Harbor Capital Management's portfolio in Q3 2019, its #391 holding.
Glen Harbor Capital Management first reported a position in Charles River Laboratories in Q4 2016 and has held it in 12 quarters since.
Glen Harbor Capital Management's Charles River Laboratories position peaked at $2.51M in Q2 2019.
396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.